Why Now Is the Time to Invest, Partner & Collaborate
ARKAY is a privately-held, clinical stage company. Leading experts in diabetes and cardiovascular disease have invested in the company. Currently, there are no anti-inflammatory 'Beta cell-centric' therapies on the market. This is why the opportunity to capitalize on this cutting-edge medicine is so great.
Our lead combination product, RK-01 was efficacious and safe in the preclinical PoC studies performed using C57BL/6J DIO (Diet-induced obesity) mice with pancreatic beta-cell dysfunction and insulin resistance*.
ARKAY's product concept has been validated by human PoC in controlled clinical studies for treating Type 2 diabetes as well as ARDS in COVID-19 patients.
ARKAY Therapeutics has established fully protected intellectual space for advancing anti-inflammatory 'Beta-cell-centric' therapies. U.S. patent US 9,839,644 B2 "Formulations and Methods for Treatment of Metabolic Syndrome” was issued on December 12, 2017. It describes in detail over 60 formulations and methods for treating Type 2 diabetes, prediabetes, and metabolic disease-related disorders. ARKAY's IND application for evaluating the superiority of TriGlytza™ over Metformin in obese type 2 diabetes patients with inadequate glycemic control was approved by the FDA in May 2018 (ClinicalTrials.gov Identifier: NCT03686657).
Gain a more in-depth view of our organization and the kinds of medication we’re creating by clicking here.
*ARKAY has been operating as a virtual company by collaborating with leading CROs